{"id":6927,"date":"2023-10-30T16:12:27","date_gmt":"2023-10-30T16:12:27","guid":{"rendered":"https:\/\/vergeva.org\/?p=6927"},"modified":"2023-10-30T16:15:01","modified_gmt":"2023-10-30T16:15:01","slug":"johnson-johnson-innovation-names-awardees-in-the-advancing-oncology-innovation-quickfire-challenge","status":"publish","type":"post","link":"https:\/\/vergeva.org\/johnson-johnson-innovation-names-awardees-in-the-advancing-oncology-innovation-quickfire-challenge\/","title":{"rendered":"Johnson & Johnson Innovation Names Awardees in the Advancing Oncology InnoVAtion QuickFire Challenge"},"content":{"rendered":"

<\/p>\n

Press release provided by Johnson & Johnson Innovation<\/a><\/em><\/p>\n

October 25th, 2023<\/strong>\u00a0\u2013 Johnson & Johnson Innovation, in collaboration with Carilion Clinic Innovation, Verge Alliance (with support from City of Roanoke), and Virginia Tech Corporate Research Center (VTCRC), announced today at the Harnessing the Potential of Antibody Drug Conjugates (ADC) in Oncology event at JLABS @ Washington D.C. that\u00a0Bacchus Therapeutics, Luminary Therapeutics, and QurCan Therapeutics Inc.,\u00a0<\/strong>have been selected as the awardees in the Advancing Oncology InnoVAtion QuickFire Challenge.<\/p>\n

The challenge invited innovators from across the globe with an active interest in the Virginia innovation ecosystem to submit potential solutions aiming to transform patient outcomes in oncology in adult populations with potential applications in pediatric oncology. The awardees hope to nurture Virginia\u2019s outstanding innovation ecosystem and spearhead innovative solutions to enhance the quality of life for cancer patients across the globe.<\/p>\n